ZIOPHARM ONCOLOGY INC License Agreements
9 Contracts & Agreements
- Fifth Amendment to Patent License Agreement, dated as of August 13, 2021, by and between the Registrant and the National Cancer Institute (Filed With SEC on March 30, 2022)
- Fourth Amendment to Patent License Agreement, dated as of May 4, 2021, by and between the Registrant and the National Cancer Institute (Filed With SEC on March 30, 2022)
- Third Amendment to Patent License Agreement, dated as of April 16, 2021, by and between the Registrant and the National Cancer Institute (Filed With SEC on March 30, 2022)
- Amendment No. 1 to the Exclusive License Agreement by and between the Registrant and PGEN Therapeutics, Inc. (formerly known as Precigen, Inc.), dated October 15, 2020 (Filed With SEC on November 5, 2020)
- Second Amendment to Patent License Agreement, dated as of September 28, 2020, by and between the Registrant and the National Cancer Institute (Filed With SEC on November 5, 2020)
- Amendment to Patent License Agreement, dated as of January 8, 2020 , by and between the Company and the National Cancer Institute (Filed With SEC on March 2, 2020)
- Patent License Agreement, dated as of May 28, 2019, by and between the Company and the National Cancer Institute (Filed With SEC on August 8, 2019)
- Exclusive License Agreement by and between the registrant, Precigen, Inc. and Intrexon Corporation, dated October 5, 2018 (Filed With SEC on November 9, 2018)
- LICENSE AGREEMENT (Filed With SEC on January 28, 2015)
